Completed
On May 20, 2024, the National Academies Forum on Drug Discovery, Development, and Translation in collaboration with the National Cancer Policy Forum, convened a public workshop for stakeholders to explore opportunities to improve representation in clinical trials with a focus on system-level change and collective efforts across organizations and sectors that no one entity can effectively take on alone. The workshop built upon previous meetings hosted by the Clinical Trials Transformation Initiative in June 2023, the Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard in September 2023, and Milken Institute's FasterCures in November 2023.
Featured publication
Workshop
·2025
Despite decades of ongoing efforts to improve racial and ethnic diversity in clinical trials, many gaps remain in achieving demographic representation in clinical studies. In May 2024, the National Academies Forum on Drug Discovery, Development, and Translation, in collaboration with the National Ca...
View details
Description
A planning committee of the National Academies of Sciences, Engineering, and Medicine will organize a public workshop to explore opportunities to improve racial and ethnic diversity in clinical trials with a focus on system-level change and collective efforts across organizations and sectors that no one entity can effectively take on alone. This workshop builds upon previous meetings hosted by the Clinical Trials Transformation Initiative in June 2023, the Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard in September 2023, and FasterCures in November 2023.
The public workshop will feature invited presentations and discussions to:
- Explore strategies for equitable participation, including innovative trial designs and partnerships to support community investment, engagement, and workforce development.
- Highlight ways that stakeholders can contribute to sustainable and scalable public awareness campaigns.
- Discuss business plans and funding mechanisms to allocate financial resources to improve clinical trial diversity.
- Consider ways to enable established and developing sites to increase capacity to conduct more equitable and representative clinical trials.
- Examine components of national, interoperable, and accountable systems for collecting and sharing condition-specific demographic data.
The planning committee will organize the workshop, develop the agenda, select and invite speakers and discussants, and moderate or identify moderators for the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.
Contributors
Committee
Chair
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Sponsors
American Association for Cancer Research
American Cancer Society
American College of Radiology
American Society of Clinical Oncology
Amgen Inc
Association of American Cancer Institutes
Association of Community Cancer Centers
AstraZeneca
Biogen
Bristol Myers Squibb
Burroughs Wellcome Fund
Cancer Support Community
Centers for Disease Control and Prevention (CDC)
Critical Path Institute
Eli Lilly and Company
FasterCures, Milken Institute
Flatiron Health
Foundation for the National Institutes of Health
Friends of Cancer Research
Johnson & Johnson
Medable
Merck & Co., Inc.
National Cancer Institute
National Center for Advancing Translational Sciences
National Comprehensive Cancer Network
National Institute of Allergy and Infectious Diseases
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
National Patient Advocate Foundation
New England Journal of Medicine
Novartis Oncology
Office of the Director (National Institutes of Health)
Oncology Nursing Society
Partners In Health
Pfizer Inc.
Sanofi
Society for Immunotherapy of Cancer
U.S. Food and Drug Administration
Staff
Alex Helman
Lead
Carolyn Shore
Lead
Erin Balogh
Lead
Sharyl Nass
Lead
Kyle Cavagnini
Noah Ontjes
Melvin Joppy
